Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction

F De Conno; A Caraceni; E Zecca; E Spoldi; V Ventafridda

doi:10.1016/0885-3924(91)90005-o

Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction

J Pain Symptom Manage. 1991 Nov;6(8):484-6. doi: 10.1016/0885-3924(91)90005-o.

Authors

F De Conno, A Caraceni, E Zecca, E Spoldi, V Ventafridda

PMID: 1720156
DOI: 10.1016/0885-3924(91)90005-o

Abstract

We describe the use of hyoscine butylbromide as a subcutaneous infusion in 3 patients with inoperable malignant bowel obstruction. An objective reduction of drainage from the gastrointestinal tract was observed with the hyoscine butylbromide infusion (60-120 mg/day). We suggest that this effect can be useful in the palliative treatment of vomiting in inoperable bowel obstruction.

MeSH terms

Aged
Butylscopolammonium Bromide / administration & dosage*
Butylscopolammonium Bromide / pharmacology
Drainage
Female
Genital Neoplasms, Female / complications
Humans
Injections, Subcutaneous
Intestinal Obstruction / etiology
Intestinal Obstruction / therapy*
Intestinal Secretions / drug effects*
Intubation, Gastrointestinal
Middle Aged
Palliative Care*

Substances

Butylscopolammonium Bromide